Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Capnia, Inc. |
---|---|
Information provided by: | Capnia, Inc. |
ClinicalTrials.gov Identifier: | NCT00484029 |
This purpose of this study is to evaluate the safety and efficacy of treatment with nasal CO2 in the treatment of pain and other symptoms related to temporomandibular disorder (TMD).
Condition | Intervention | Phase |
---|---|---|
Temporomandibular Disorders Pain Headaches |
Drug: Nasal Carbon Dioxide Other: Air |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Nasal CO2 in the Symptomatic Treatment of Temporomandibular Disorders |
Enrollment: | 100 |
Study Start Date: | February 2007 |
Estimated Study Completion Date: | December 2008 |
Primary Completion Date: | October 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Nasal Carbon Dioxide
|
Drug: Nasal Carbon Dioxide
Nasal Carbon Dioxide
|
2: Placebo Comparator
Air
|
Other: Air
Air (Medical Grade)
|
This is a randomized, controlled trial evaluating the safety and efficacy of nasal carbon dioxide for the treatment of pain and other symptoms related to temporomandibular disorders (TMD). Approximately 115 men and women ages 18 to 70 years old who have a history consistent with TMD-related pain for at least 3 months and meet all other eligibility criteria will be enrolled in this study. There may be up to two (2) visits to the clinic, screening and treatment. Screening and treatment may occur on the same day.
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
Key Exclusion Criteria:
United States, Washington | |
University of Washington, Department of Oral Medicine, Box 356370, Health Sciences Building | |
Seattle, Washington, United States, 98195 |
Principal Investigator: | Edward L. Truelove, DDS, MSD | University of Washington School of Dentistry |
Responsible Party: | Capnia, Inc. ( Kristen Yen- Associate Director, Clinical ) |
Study ID Numbers: | C301 |
Study First Received: | June 7, 2007 |
Last Updated: | November 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00484029 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Temporomandibular Disorders TMD TMJ/TMD |
Pain Management Pain Headaches |
Fibromyalgia Myofascial Pain Syndromes Joint Diseases Pain Signs and Symptoms Temporomandibular Joint Disorders Muscular Diseases |
Temporomandibular Joint Dysfunction Syndrome Musculoskeletal Diseases Craniomandibular Disorders Headache Neurologic Manifestations Stomatognathic Diseases |
Mandibular Diseases Disease Myofascial Pain Syndromes Joint Diseases Nervous System Diseases Jaw Diseases Pain Signs and Symptoms Temporomandibular Joint Disorders |
Muscular Diseases Pathologic Processes Temporomandibular Joint Dysfunction Syndrome Musculoskeletal Diseases Craniomandibular Disorders Headache Neurologic Manifestations Stomatognathic Diseases |